[go: up one dir, main page]

WO2008101671A3 - Il-4 fc fusion proteins - Google Patents

Il-4 fc fusion proteins Download PDF

Info

Publication number
WO2008101671A3
WO2008101671A3 PCT/EP2008/001293 EP2008001293W WO2008101671A3 WO 2008101671 A3 WO2008101671 A3 WO 2008101671A3 EP 2008001293 W EP2008001293 W EP 2008001293W WO 2008101671 A3 WO2008101671 A3 WO 2008101671A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion proteins
domain
relates
constant immunoglobulin
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/001293
Other languages
French (fr)
Other versions
WO2008101671A9 (en
WO2008101671A2 (en
Inventor
Oliver Hill
Christian Gieffers
Meinolf Thiemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apogenix AG
Original Assignee
Apogenix AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix AG filed Critical Apogenix AG
Publication of WO2008101671A2 publication Critical patent/WO2008101671A2/en
Publication of WO2008101671A3 publication Critical patent/WO2008101671A3/en
Publication of WO2008101671A9 publication Critical patent/WO2008101671A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to fusion proteins comprising at least one IL-4 polypeptide domain and a constant immunoglobulin domain.
PCT/EP2008/001293 2007-02-19 2008-02-19 Il-4 fc fusion proteins Ceased WO2008101671A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07003443.4 2007-02-19
EP07003443 2007-02-19

Publications (3)

Publication Number Publication Date
WO2008101671A2 WO2008101671A2 (en) 2008-08-28
WO2008101671A3 true WO2008101671A3 (en) 2008-12-11
WO2008101671A9 WO2008101671A9 (en) 2009-02-19

Family

ID=39670915

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/001293 Ceased WO2008101671A2 (en) 2007-02-19 2008-02-19 Il-4 fc fusion proteins

Country Status (1)

Country Link
WO (1) WO2008101671A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623693B (en) * 2017-03-20 2022-03-25 徐寒梅 Fusion protein, preparation method thereof and application thereof in preparing medicaments for treating ophthalmic diseases, anti-inflammatory and antitumor

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112871A1 (en) 2012-01-27 2013-08-01 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic il-13 polypeptides
RU2648157C2 (en) * 2012-07-18 2018-03-22 Аподжиникс Аг Composition comprising mixture of cd95-fc isofroms
IN2015KN00329A (en) 2012-08-09 2015-07-10 Univ Leland Stanford Junior
JP6936934B2 (en) 2013-09-24 2021-09-22 メディシナ セラピューティクス インコーポレイテッド Interleukin-4 receptor binding fusion protein and its use
JP2020520671A (en) * 2017-05-24 2020-07-16 ノバルティス アーゲー Antibody-cytokine grafted proteins and methods of use
WO2019073299A1 (en) 2017-10-10 2019-04-18 Medicenna Therapeutics, Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
US12404497B2 (en) 2018-06-01 2025-09-02 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof
EP4285913A1 (en) * 2022-05-30 2023-12-06 Ecole Polytechnique Fédérale de Lausanne (EPFL) Highly effective adoptive t cell therapy
EP4612165A1 (en) * 2022-11-02 2025-09-10 Synerkine Pharma B.V. Engineered immunocytokines, fusion polypeptides, and il10 polypeptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US6130318A (en) * 1994-07-01 2000-10-10 Bayer Aktiengellschaft hIL-4 mutant proteins used as antagonists or partial agonists of human interleukin 4
WO2001003737A1 (en) * 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Immunoglobulin fusion proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130318A (en) * 1994-07-01 2000-10-10 Bayer Aktiengellschaft hIL-4 mutant proteins used as antagonists or partial agonists of human interleukin 4
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
WO2001003737A1 (en) * 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Immunoglobulin fusion proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PICCIRILLO C ET AL: "Prevention of experimental allergic encephalomyelitis by intramuscular gene transfer with cytokine-encoding plasmid vectors", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 10, 10 August 1999 (1999-08-10), pages 1915 - 1922, XP002202211, ISSN: 1043-0342 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623693B (en) * 2017-03-20 2022-03-25 徐寒梅 Fusion protein, preparation method thereof and application thereof in preparing medicaments for treating ophthalmic diseases, anti-inflammatory and antitumor

Also Published As

Publication number Publication date
WO2008101671A9 (en) 2009-02-19
WO2008101671A2 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
WO2008101671A3 (en) Il-4 fc fusion proteins
WO2012142515A3 (en) Fc fusion proteins comprising novel linkers or arrangements
IL202128A0 (en) Immunoglobulin fusion proteins
WO2004085478A3 (en) Improved fc fusion proteins
WO2008030558A3 (en) Modified human plasma polypeptide or fc scaffolds and their uses
BRPI0807480A2 (en) CONNECTING, IMMUNOGLOBULIN G, COMPOSITION AND FUSION PROTEIN
WO2006104989A3 (en) Altered antibody fc regions and uses thereof
WO2006061219A3 (en) Il-7 variants with reduced immunogenicity
IL218296A0 (en) Obpgplys/endolysin polypeptides, fusion proteins and compositions compriisng the same and uses thereof
WO2007060117A3 (en) Chimeric keratin-binding effector proteins
WO2006105338A3 (en) Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2007041635A3 (en) Fc variants with optimized fc receptor binding properties
WO2006031370A3 (en) Polypeptide variants with altered effector function
IL222924A0 (en) Albumin fusion proteins
IL197580A0 (en) Albumin fusion proteins
WO2008092117A3 (en) Immunoglobulins with modifications in the fcr binding region
IL204839A0 (en) Albumin fusion proteins
EP1877437A4 (en) Chimeric proteins with phosphatidylserine binding domains
EP1934372A4 (en) Ssb - polymerase fusion proteins
WO2008086035A3 (en) Split mutant hydrolase fusion reporter and uses thereof
WO2010014922A3 (en) Protein purification tags and uses thereof
GB2441208B (en) Fusion protein of fc-binding domain and calcium-binding photoprotein,gene encoding the same and use thereof
WO2009081170A3 (en) Peptide fusion proteins
WO2010004338A3 (en) Proteins comprising affinity tag for two distinct targets
HK40068662A (en) Apoe antibodies, fusion proteins and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08734585

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08734585

Country of ref document: EP

Kind code of ref document: A2